| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| PLRZPolyrizon Ltd. | 16.19M | 15.54 | 31.08 | -5.21% | ||||
| TOVXTheriva Biologics, Inc. | 7.49M | 0.21 | -0.01 | -388.69% | 0.08 | |||
| CTXRCitius Pharmaceuticals, Inc. | 17.79M | 0.86 | -0.14 | -258.23% | -59.6% | 0.00 | ||
| ACXPAcurx Pharmaceuticals, Inc. | 6.32M | 2.69 | -0.15 | -0.25% | ||||
| ITRMIterum Therapeutics plc | 17.16M | 0.32 | -0.26 | -69.13% | ||||
| ANTXAN2 Therapeutics, Inc. | 34.25M | 1.25 | -0.73 | -56.29% | ||||
| MCRBSeres Therapeutics, Inc. | 137.33M | 15.18 | -0.80 | 15.37% | 12.34% | 6.65 | ||
| PYPDPolyPid Ltd. | 73.03M | 4.39 | -0.89 | -10.39% | 1.25 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 1.2M | 835K | 335K | 153K | 7.91M | 12.63M | 5.17M | 6.07M | 7.3M | 7.81M |
| Revenue Growth % | 2.41% | -0.3% | -0.6% | -0.54% | 50.7% | 0.6% | -0.59% | 0.17% | 0.2% | 0.07% |
| Cost of Goods Sold | 7.19M | 10.15M | 10.24M | 12.97M | 12.85M | 0 | 15.38M | 18.24M | 15.52M | 7.17M |
| COGS % of Revenue | 5.98% | 12.16% | 30.58% | 84.75% | 1.62% | - | 2.98% | 3% | 2.13% | 0.92% |
| Gross Profit | -5.99M | -9.32M | -9.91M | -12.81M | -4.93M | 12.63M | -10.21M | -12.17M | -8.22M | 640K |
| Gross Margin % | -4.98% | -11.16% | -29.58% | -83.75% | -0.62% | 1% | -1.98% | -2% | -1.13% | 0.08% |
| Gross Profit Growth % | 0.04% | -0.56% | -0.06% | -0.29% | 0.61% | 3.56% | -1.81% | -0.19% | 0.32% | 1.08% |
| Operating Expenses | 17.03M | 15.55M | 7.57M | 7.59M | 15.76M | 22.5M | 9.95M | 6.78M | 6.52M | 10.4M |
| OpEx % of Revenue | 14.18% | 18.62% | 22.59% | 49.59% | 1.99% | 1.78% | 1.93% | 1.12% | 0.89% | 1.33% |
| Selling, General & Admin | 9.63M | 8.02M | 7.57M | 7.52M | 8.49M | 6.89M | 6.38M | 6.78M | 6.52M | 7.79M |
| SG&A % of Revenue | 8.02% | 9.6% | 22.59% | 49.14% | 1.07% | 0.55% | 1.23% | 1.12% | 0.89% | 1% |
| Research & Development | 7.19M | 17.69M | 10.24M | 12.97M | 12.85M | 15.61M | 15.38M | 18.24M | 15.52M | 7.17M |
| R&D % of Revenue | 5.98% | 21.18% | 30.58% | 84.75% | 1.62% | 1.24% | 2.98% | 3% | 2.13% | 0.92% |
| Other Operating Expenses | 213K | -10.15M | -10.24M | -12.9M | -5.58M | 0 | -11.8M | -18.24M | -15.52M | -4.55M |
| Operating Income | -23.02M | -24.87M | -17.48M | -20.4M | -20.69M | -9.86M | -20.17M | -18.95M | -14.74M | -9.76M |
| Operating Margin % | -19.17% | -29.78% | -52.16% | -133.33% | -2.62% | -0.78% | -3.9% | -3.12% | -2.02% | -1.25% |
| Operating Income Growth % | -1.54% | -0.08% | 0.3% | -0.17% | -0.01% | 0.52% | -1.04% | 0.06% | 0.22% | 0.34% |
| EBITDA | -22.79M | -24.62M | -17.23M | -20.17M | -20.51M | -9.65M | -20M | -18.79M | -14.61M | -9.66M |
| EBITDA Margin % | -18.97% | -29.48% | -51.43% | -131.82% | -2.59% | -0.76% | -3.87% | -3.09% | -2% | -1.24% |
| EBITDA Growth % | -1.61% | -0.08% | 0.3% | -0.17% | -0.02% | 0.53% | -1.07% | 0.06% | 0.22% | 0.34% |
| D&A (Non-Cash Add-back) | 232K | 250K | 246K | 231K | 182K | 215K | 169K | 162K | 134K | 106K |
| EBIT | -15.62M | -17.33M | -17.48M | -20.33M | -13.42M | -9.86M | -16.59M | -18.95M | -14.74M | -7.14M |
| Net Interest Income | -953K | -881K | -643K | -159K | 301K | 82K | 7K | 309K | 867K | 467K |
| Interest Income | 0 | 0 | 0 | 27K | 301K | 82K | 7K | 309K | 867K | 467K |
| Interest Expense | 953K | 881K | 643K | 186K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -3.15M | -5.94M | -581K | -163K | 96K | -9.45M | -4K | 111K | 619K | 204K |
| Pretax Income | -26.17M | -30.8M | -18.06M | -20.56M | -20.6M | -19.31M | -20.17M | -18.84M | -14.12M | -9.56M |
| Pretax Margin % | -21.79% | -36.89% | -53.9% | -134.4% | -2.6% | -1.53% | -3.9% | -3.1% | -1.93% | -1.22% |
| Income Tax | 0 | -2.96M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 0.9% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -26.17M | -27.84M | -18.06M | -20.56M | -20.6M | -19.31M | -20.17M | -18.84M | -14.12M | -9.56M |
| Net Margin % | -21.79% | -33.34% | -53.9% | -134.4% | -2.6% | -1.53% | -3.9% | -3.1% | -1.93% | -1.22% |
| Net Income Growth % | -0.08% | -0.06% | 0.35% | -0.14% | -0% | 0.06% | -0.04% | 0.07% | 0.25% | 0.32% |
| Net Income (Continuing) | -26.17M | -27.84M | -18.06M | -20.56M | -20.6M | -19.31M | -20.17M | -18.84M | -14.12M | -9.56M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -646.91 | -375.87 | -186.42 | -99.67 | -24.37 | -19.83 | -8.31 | -5.43 | -3.87 | -2.62 |
| EPS Growth % | 0.16% | 0.42% | 0.5% | 0.47% | 0.76% | 0.19% | 0.58% | 0.35% | 0.29% | 0.32% |
| EPS (Basic) | -646.91 | -375.87 | -186.42 | -99.67 | -24.37 | -19.83 | -8.31 | -5.43 | -3.87 | -2.62 |
| Diluted Shares Outstanding | 40.45K | 74.08K | 96.86K | 206.32K | 836.7K | 1.44M | 2.71M | 3.45M | 3.65M | 3.65M |
| Basic Shares Outstanding | 40.45K | 74.08K | 96.86K | 206.32K | 836.7K | 1.44M | 2.34M | 3.45M | 3.65M | 3.65M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 20.46M | 4.76M | 4.25M | 3.28M | 31.42M | 32.54M | 54.78M | 38.15M | 20.84M | 9.92M |
| Cash & Short-Term Investments | 18.9M | 4.18M | 3.55M | 2.56M | 23.44M | 31.66M | 53.84M | 35.63M | 19.17M | 9.52M |
| Cash Only | 18.9M | 4.18M | 3.55M | 2.56M | 23.44M | 31.66M | 53.84M | 35.63M | 19.17M | 9.52M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 481K | 206K | 1K | 0 | 7.2M | 84K | 67K | 1.3M | 928K | 0 |
| Days Sales Outstanding | 146.18 | 90.05 | 1.09 | - | 332.24 | 2.43 | 4.73 | 78.04 | 46.41 | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 667K | 0 | 153K | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | 3.06 | - | - |
| Other Current Assets | 598K | 107K | 71K | 55K | 253K | -593K | 0 | 166K | 372K | 180K |
| Total Non-Current Assets | 24.41M | 11.9M | 11.73M | 11.44M | 4.68M | 5.63M | 4.04M | 2.81M | 13.12M | 23K |
| Property, Plant & Equipment | 685K | 786K | 614K | 394K | 900K | 1.85M | 2.41M | 945K | 11.47M | 0 |
| Fixed Asset Turnover | 1.75x | 1.06x | 0.55x | 0.39x | 8.79x | 6.83x | 2.14x | 6.42x | 0.64x | - |
| Goodwill | 15.94M | 10.91M | 10.91M | 10.85M | 3.58M | 3.58M | 0 | 0 | 0 | 0 |
| Intangible Assets | 7.53M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 250K | 204K | 204K | 204K | 204K | 0 | 1.63M | 1.47M | 1.47M | 10K |
| Other Non-Current Assets | 250K | 204K | 204K | 204K | 204K | 204K | 0 | 389K | 176K | 13K |
| Total Assets | 44.87M | 16.66M | 15.98M | 14.72M | 36.1M | 38.17M | 58.82M | 40.95M | 33.96M | 9.94M |
| Asset Turnover | 0.03x | 0.05x | 0.02x | 0.01x | 0.22x | 0.33x | 0.09x | 0.15x | 0.21x | 0.79x |
| Asset Growth % | 1.88% | -0.63% | -0.04% | -0.08% | 1.45% | 0.06% | 0.54% | -0.3% | -0.17% | -0.71% |
| Total Current Liabilities | 3.6M | 4.65M | 5.84M | 2.88M | 17.2M | 8.25M | 4.44M | 5.02M | 3.91M | 929K |
| Accounts Payable | 1.09M | 747K | 457K | 1.18M | 600K | 851K | 839K | 1.19M | 1.92M | 809K |
| Days Payables Outstanding | 55.36 | 26.86 | 16.28 | 33.3 | 17.05 | - | 19.91 | 23.77 | 45.04 | 41.21 |
| Short-Term Debt | 1.03M | 2.59M | 3.22M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 4K | 0 | 0 | 67K | 1000K | 1000K | 939K | 1000K | 618K | 0 |
| Other Current Liabilities | 764K | 842K | 138K | 0 | 1.95M | 1.23M | 182K | 508K | 877K | 71K |
| Current Ratio | 5.68x | 1.02x | 0.73x | 1.14x | 1.83x | 3.94x | 12.33x | 7.60x | 5.33x | 10.68x |
| Quick Ratio | 5.68x | 1.02x | 0.73x | 1.14x | 1.83x | 3.86x | 12.33x | 7.57x | 5.33x | 10.68x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | 57.33 | - | - |
| Total Non-Current Liabilities | 8.66M | 3.25M | 1K | 0 | 7.88M | 6.78M | 6.93M | 4.82M | 12.05M | 67K |
| Long-Term Debt | 5.69M | 3.22M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 608K | 857K | 0 | 8.33M | 0 |
| Deferred Tax Liabilities | 2.96M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 11K | 35K | 1K | 0 | 0 | 0 | 0 | 0 | 0 | 67K |
| Total Liabilities | 12.27M | 7.9M | 5.84M | 2.88M | 25.08M | 15.03M | 11.37M | 9.84M | 15.96M | 996K |
| Total Debt | 6.72M | 5.8M | 3.22M | 0 | 675K | 1.74M | 2.29M | 857K | 8.76M | 0 |
| Net Debt | -12.18M | 1.62M | -329K | -2.56M | -22.77M | -29.91M | -51.55M | -34.77M | -10.42M | -9.52M |
| Debt / Equity | 0.21x | 0.66x | 0.32x | - | 0.06x | 0.08x | 0.05x | 0.03x | 0.49x | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -24.15x | -28.22x | -27.18x | -109.68x | - | - | - | - | - | - |
| Total Equity | 32.61M | 8.76M | 10.14M | 11.84M | 11.02M | 23.14M | 47.45M | 31.11M | 18M | 8.95M |
| Equity Growth % | 1.23% | -0.73% | 0.16% | 0.17% | -0.07% | 1.1% | 1.05% | -0.34% | -0.42% | -0.5% |
| Book Value per Share | 806.10 | 118.27 | 104.66 | 57.41 | 13.17 | 16.09 | 17.52 | 9.02 | 4.93 | 2.45 |
| Total Shareholders' Equity | 32.61M | 8.76M | 10.14M | 11.84M | 11.02M | 23.14M | 47.45M | 31.11M | 18M | 8.95M |
| Common Stock | 1K | 1K | 2K | 0 | 2K | 4K | 0 | 0 | 0 | 0 |
| Retained Earnings | -128.1M | -155.95M | -174M | -194.56M | -215.16M | -234.47M | -254.64M | -273.48M | -287.6M | -297.16M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | -2.67M | -2.87M | -2.12M | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -12.47M | -13.24M | -14.48M | -16.76M | 3.23M | -12.48M | -19.73M | -19.36M | -15.98M | -10.72M |
| Operating CF Margin % | -10.38% | -15.86% | -43.21% | -109.55% | 0.41% | -0.99% | -3.82% | -3.19% | -2.19% | -1.37% |
| Operating CF Growth % | -3.2% | -0.06% | -0.09% | -0.16% | 1.19% | -4.86% | -0.58% | 0.02% | 0.17% | 0.33% |
| Net Income | -26.17M | -27.84M | -18.06M | -20.56M | -20.6M | -19.31M | -20.17M | -18.84M | -14.12M | -9.56M |
| Depreciation & Amortization | 232K | 250K | 246K | 231K | 765K | 1.04M | 1.24M | 1.54M | 1.48M | 435K |
| Stock-Based Compensation | 9.76M | 4M | 2.82M | 2.97M | 2.07M | 1.16M | 1.16M | 1.11M | 954K | 511K |
| Deferred Taxes | 1.18M | 9.69M | -34K | 76K | 0 | 0 | 0 | -4.92M | 0 | 0 |
| Other Non-Cash Items | 1.64M | 295K | 204K | 38K | 7.27M | 9.29M | 3.58M | 4.92M | 8K | 2.69M |
| Working Capital Changes | 884K | 371K | 345K | 484K | 13.73M | -4.67M | -5.53M | -3.18M | -4.3M | -4.79M |
| Change in Receivables | 0 | 0 | 0 | 0 | -7.2M | 7.12M | 17K | -1.23M | 370K | 928K |
| Change in Inventory | 0 | 0 | 0 | 0 | 220K | -1.13M | -2.07M | 0 | 0 | 0 |
| Change in Payables | 806K | -346K | -290K | 726K | -583K | 300K | -149K | 511K | 727K | -1.11M |
| Cash from Investing | 9.4M | -431K | -74K | -19K | -58K | -281K | -144K | -86K | -676K | -398K |
| Capital Expenditures | -266K | -455K | -74K | -19K | -58K | -281K | -144K | -86K | -676K | -398K |
| CapEx % of Revenue | 0.22% | 0.54% | 0.22% | 0.12% | 0.01% | 0.02% | 0.03% | 0.01% | 0.09% | 0.05% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 24K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 21.52M | -1.05M | 13.92M | 15.79M | 17.7M | 20.98M | 43.48M | 1.23M | 53K | 0 |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | -3.2M | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 151K | 0 | 304K | 0 | 160K | 13.67M | 3.4M | 0 | 0 | 0 |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -12.74M | -13.7M | -14.55M | -16.78M | 3.17M | -12.76M | -19.87M | -19.44M | -16.66M | -11.11M |
| FCF Margin % | -10.61% | -16.4% | -43.44% | -109.67% | 0.4% | -1.01% | -3.84% | -3.2% | -2.28% | -1.42% |
| FCF Growth % | -3.08% | -0.08% | -0.06% | -0.15% | 1.19% | -5.02% | -0.56% | 0.02% | 0.14% | 0.33% |
| FCF per Share | -314.92 | -184.92 | -150.23 | -81.33 | 3.79 | -8.88 | -7.34 | -5.64 | -4.56 | -3.04 |
| FCF Conversion (FCF/Net Income) | 0.48x | 0.48x | 0.80x | 0.82x | -0.16x | 0.65x | 0.98x | 1.03x | 1.13x | 1.12x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -110.8% | -134.61% | -191.09% | -187.1% | -180.17% | -113.05% | -57.15% | -47.95% | -57.51% | -70.96% |
| Return on Invested Capital (ROIC) | -58.34% | -121.07% | -129.83% | -160.3% | - | - | - | - | -564.61% | -209.09% |
| Gross Margin | -498.42% | -1115.81% | -2957.61% | -8374.51% | -62.39% | 100% | -197.58% | -200.44% | -112.63% | 8.2% |
| Net Margin | -2178.77% | -3334.49% | -5389.85% | -13439.87% | -260.38% | -152.83% | -390.23% | -310.26% | -193.49% | -122.46% |
| Debt / Equity | 0.21x | 0.66x | 0.32x | - | 0.06x | 0.08x | 0.05x | 0.03x | 0.49x | - |
| Interest Coverage | -24.15x | -28.22x | -27.18x | -109.68x | - | - | - | - | - | - |
| FCF Conversion | 0.48x | 0.48x | 0.80x | 0.82x | -0.16x | 0.65x | 0.98x | 1.03x | 1.13x | 1.12x |
| Revenue Growth | 241.19% | -30.47% | -59.88% | -54.33% | 5069.93% | 59.72% | -59.09% | 17.45% | 20.21% | 6.96% |
| 2015 | 2016 | 2020 | |
|---|---|---|---|
| Toxicology Study Costs | - | - | 1.65M |
| Toxicology Study Costs Growth | - | - | - |
| Long Acting Muscarinic Agent Collaboration Agreement | 1.02M | 835K | - |
| Long Acting Muscarinic Agent Collaboration Agreement Growth | - | -18.06% | - |
| Material Transfer Agreement | 77K | - | - |
| Material Transfer Agreement Growth | - | - | - |
Pulmatrix, Inc. (PULM) reported $0.0M in revenue for fiscal year 2024.
Pulmatrix, Inc. (PULM) grew revenue by 7.0% over the past year. This is steady growth.
Pulmatrix, Inc. (PULM) reported a net loss of $6.2M for fiscal year 2024.
Pulmatrix, Inc. (PULM) has a return on equity (ROE) of -71.0%. Negative ROE indicates the company is unprofitable.
Pulmatrix, Inc. (PULM) had negative free cash flow of $6.0M in fiscal year 2024, likely due to heavy capital investments.